BEGEV is an Effective Therapy for Heavily Pretreated and Platinum-Resistant Relapsed/Refractory Hodgkin's Lymphoma Patients: A Single Center Real-Life Experience

Sadeleştirilmiş öğe sayfası
dc.contributor.authorUzay, Ant
dc.contributor.authorTasci, Elif Senocak
dc.contributor.authorGundogdu, Yasemin
dc.contributor.authorMutlu, Arda Ulas
dc.contributor.authorYetis, Tugba
dc.contributor.authorKosan, Baris
dc.contributor.authorKarti, Sami
dc.date.accessioned2025-10-16T15:12:24Z
dc.date.issued2024
dc.identifier.doi10.1007/s12288-024-01924-6
dc.identifier.otherWOS:001366343800001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/5416
dc.publisherSPRINGER INDIA
dc.sourceINDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
dc.subjectBEGEV
dc.subjectPretreated
dc.subjectHodgkin
dc.subjectLymphoma
dc.subjectPlatinum\\-resistant
dc.subjectRelaped\\-refractory
dc.titleBEGEV is an Effective Therapy for Heavily Pretreated and Platinum-Resistant Relapsed/Refractory Hodgkin's Lymphoma Patients: A Single Center Real-Life Experience
dc.typeArticle; Early Access

Dosyalar

Koleksiyonlar

WOS